Since hypoxia-inducible factor (HIF)-1a is one of the key regulators for the differentiation and accumulation of MDSCs in hypoxic tumor regions [37,38], targeting HIF-1a might improve anti-tumor immune responses in patients with anti-PD1 Abs. The gene discussed is HIF1A; the disease is neoplasm.